BTPC Stock Overview
A biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Active Biotech AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.012 |
| 52 Week High | SEK 0.13 |
| 52 Week Low | SEK 0.0032 |
| Beta | 0.48 |
| 11 Month Change | -56.34% |
| 3 Month Change | -57.97% |
| 1 Year Change | -63.53% |
| 33 Year Change | -87.75% |
| 5 Year Change | -94.05% |
| Change since IPO | -99.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| BTPC | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -15.1% | -0.7% | -0.02% |
| 1Y | -63.5% | -17.2% | 8.2% |
Return vs Industry: BTPC underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: BTPC underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| BTPC volatility | |
|---|---|
| BTPC Average Weekly Movement | 82.3% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: BTPC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: BTPC's weekly volatility has increased from 53% to 82% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 6 | Helen Tuvesson | www.activebiotech.com |
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that has completed phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Active Biotech AB (publ) Fundamentals Summary
| BTPC fundamental statistics | |
|---|---|
| Market cap | €26.74m |
| Earnings (TTM) | -€3.62m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.4x
P/E RatioIs BTPC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BTPC income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 41.60m |
| Earnings | -SEK 41.60m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -0.034 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BTPC perform over the long term?
See historical performance and comparison